In the phase 3 RASolute 302 trial, daraxonrasib improved overall survival and progression-free survival vs chemotherapy in patients with second-line metastatic pancreatic adenocarcinoma.
The FDA approved Baxfendy as an adjunctive treatment to lower blood pressure in adults with hypertension not adequately controlled on other antihypertensive medications.
On May 22, 2026, the FDA approved datopotamab deruxtecan-dlnk for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy, based on...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, will address migraine-related diagnosis, treatment, red flags, and care considerations across...
In this expert interview, W. Clay Jackson, MD, DipTh, discusses why deprescribing should be approached through shared decision-making, careful medication review, and attention to each patient’s current...
Many patients with major depressive disorder remain “stuck” in partial response despite treatment. In this Practical Updates in Primary Care recap, Rakesh Jain, MD, MPH, outlines strategies to identify...
A randomized clinical trial evaluated whether behavioral science–informed electronic health record interventions can improve deprescribing rates of potentially inappropriate medications among older adults...
